This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Labbé, A.-C.
Right arrow Articles by Lamothe, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Labbé, A.-C.
Right arrow Articles by Lamothe, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 1999, p. 2517-2519, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Trends in Antimicrobial Resistance among Clinical Isolates of the Bacteroides fragilis Group from 1992 to 1997 in Montreal, Canada

Annie-Claude Labbé, Anne-Marie Bourgault, Jean Vincelette, Pierre L. Turgeon, and François Lamothe*

Département de Microbiologie Médicale et Infectiologie, Centre Hospitalier de l'Université de Montréal, Montréal, Canada

Received 26 April 1999/Returned for modification 9 June 1999/Accepted 29 July 1999

The objective of the present study was to analyze the susceptibility profiles of 911 clinical strains of the Bacteroides fragilis group isolated from 1992 to 1997 in our institution in order to monitor susceptibility changes over time. Whereas the rates of resistance to metronidazole, imipenem, piperacillin-tazobactam, ticarcillin-clavulanic acid, penicillin, piperacillin, and cefoxitin remained essentially unchanged, there was a significant increase in the rates of resistance to clindamycin, which rose from 8.2% in 1992 to 19.7% in 1997 (P < 0.0004).

* Corresponding author. Mailing address: Département de Microbiologie Médicale et Infectiologie, Centre Hospitalier de l'Université de Montréal, Campus Saint-Luc, 1058 St-Denis, Montréal, Québec, Canada H2X 3J4. Phone: (514) 281-2100. Fax: (514) 281-2443. E-mail: lamothef{at}ere.umontreal.ca.

Antimicrobial Agents and Chemotherapy, October 1999, p. 2517-2519, Vol. 43, No. 10
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Liu, C.-Y., Huang, Y.-T., Liao, C.-H., Yen, L.-C., Lin, H.-Y., Hsueh, P.-R. (2008). Increasing Trends in Antimicrobial Resistance among Clinically Important Anaerobes and Bacteroides fragilis Isolates Causing Nosocomial Infections: Emerging Resistance to Carbapenems. Antimicrob. Agents Chemother. 52: 3161-3168 [Abstract] [Full Text]  
  • Hecht, D. W., Osmolski, J. R. (2003). Activities of Garenoxacin (BMS-284756) and Other Agents against Anaerobic Clinical Isolates. Antimicrob. Agents Chemother. 47: 910-916 [Abstract] [Full Text]  
  • Teng, L.-J., Hsueh, P.-R., Tsai, J.-C., Liaw, S.-J., Ho, S.-W., Luh, K.-T. (2002). High Incidence of Cefoxitin and Clindamycin Resistance among Anaerobes in Taiwan. Antimicrob. Agents Chemother. 46: 2908-2913 [Abstract] [Full Text]  
  • Betriu, C., Sanchez, A., Palau, M. L., Gomez, M., Picazo, J. J. (2001). In Vitro Activities of MK-0826 and 16 Other Antimicrobials against Bacteroides fragilis Group Strains. Antimicrob. Agents Chemother. 45: 2372-2374 [Abstract] [Full Text]  
  • Aldridge, K. E., Ashcraft, D., Cambre, K., Pierson, C. L., Jenkins, S. G., Rosenblatt, J. E. (2001). Multicenter Survey of the Changing In Vitro Antimicrobial Susceptibilities of Clinical Isolates of Bacteroides fragilis Group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus Species. Antimicrob. Agents Chemother. 45: 1238-1243 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»